Successful treatment of severe @entity295 and XXXX after vagotomy utilizing @entity8 : a case report.

@entity1 @entity32 @entity8 @entity295 @entity326 @entity294 @entity6636 @entity2259
INTRODUCTION: Dysbiosis of intestinal microbiota likely plays an important role in the development of gut-derived infections, making it a potential therapeutic target against @entity295 . However, experience with @entity8 ( @entity8 ) in the treatment of @entity295 and knowledge of the underlying mechanisms are extremely lacking. In this article, we describe a case of a @entity1 who developed @entity295 after a vagotomy and later received an infusion of donor feces microbiota, and we report our findings. METHODS: A 44-year-old @entity1 developed @entity326 and severe watery @entity294 4 days after undergoing a vagotomy. Antibiotics, probiotics and supportive treatment strategies were used for about 30 day after surgery, but the @entity1 's fever, @entity2259 and watery @entity294 persisted. Considering the possibility of @entity6636 , we evaluated the structure and composition of the @entity1 's fecal microbiota using 16S rDNA-based molecular techniques. As expected, the gut microbiota was extensively disrupted; therefore, a donor fecal suspension was delivered into the @entity1 by nasoduodenal tube. The @entity1 's clinical outcomes and shifts of the gut microbiota following the treatment were also determined. RESULTS: Dramatically, the @entity1 's septic symptoms and severe @entity294 were successfully controlled following @entity8 . Her stool output markedly declined after 7 days and normalized 16 days after @entity8 . A significant modification in her microbiota composition was consistently seen, characterized by a profound enrichment of the commensals in Firmicutes and depletion of opportunistic organisms in Proteobacteria. Furthermore, we identified a reconstituted bacterial community enriched in Firmicutes and depleted of Proteobacteria members that was associated with fecal output, plasma markers of @entity32 and T helper cells. CONCLUSIONS: In this report, we describe our initial experience with @entity8 , in which we successfully used it in the treatment of a @entity1 with @entity295 and severe @entity294 after a vagotomy. Our data indicate an association between repaired intestinal microbiota barrier and improvement of clinical outcomes. Our @entity1 's surprising clinical benefits from @entity8 demonstrate the role of intestinal microbiota in modulating immune equilibrium. It represents a breakthrough in the clinical management of @entity295 and suggests new therapeutic avenues to pursue for microbiota-related indications.
